James W. Hainer

1.1k total citations
23 papers, 722 citations indexed

About

James W. Hainer is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, James W. Hainer has authored 23 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 7 papers in Surgery and 6 papers in Internal Medicine. Recurrent topics in James W. Hainer's work include Venous Thromboembolism Diagnosis and Management (6 papers), Blood Pressure and Hypertension Studies (5 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (3 papers). James W. Hainer is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (6 papers), Blood Pressure and Hypertension Studies (5 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (3 papers). James W. Hainer collaborates with scholars based in United States, United Kingdom and Germany. James W. Hainer's co-authors include Jennifer Sugg, Jeffrey S. Barrett, Jonathan M. Sorof, Karl Swedberg, Bertil Olofsson, Salim Yusuf, James B. Young, John J.V. McMurray, Michael J. Fossler and Mark E. Dunlap and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and CHEST Journal.

In The Last Decade

James W. Hainer

22 papers receiving 670 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James W. Hainer United States	15	429	148	147	143	142	23	722
Argyri Gialeraki Greece	18	246 0.6×	108 0.7×	102 0.7×	112 0.8×	96 0.7×	41	789
Young‐Rak Cho South Korea	17	574 1.3×	59 0.4×	405 2.8×	138 1.0×	151 1.1×	73	995
Daan van de Kerkhof Netherlands	16	249 0.6×	138 0.9×	91 0.6×	52 0.4×	63 0.4×	55	805
A. Ravani Italy	13	432 1.0×	60 0.4×	104 0.7×	174 1.2×	85 0.6×	31	808
Maximilian T. Lobmeyer United States	14	1.1k 2.6×	384 2.6×	146 1.0×	87 0.6×	141 1.0×	26	1.6k
Steven R. Kayser United States	13	220 0.5×	63 0.4×	271 1.8×	54 0.4×	47 0.3×	26	776
Chi‐Ren Hung Taiwan	15	483 1.1×	28 0.2×	277 1.9×	392 2.7×	178 1.3×	34	1.2k
D. Baron Australia	12	578 1.3×	43 0.3×	390 2.7×	124 0.9×	146 1.0×	35	942
Steen Dalby Kristensen Denmark	14	890 2.1×	313 2.1×	352 2.4×	79 0.6×	85 0.6×	21	1.3k
S. Renaud France	14	208 0.5×	42 0.3×	184 1.3×	71 0.5×	81 0.6×	34	659

Countries citing papers authored by James W. Hainer

Since Specialization

Citations

This map shows the geographic impact of James W. Hainer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Hainer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Hainer more than expected).

Fields of papers citing papers by James W. Hainer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. Hainer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Hainer. The network helps show where James W. Hainer may publish in the future.

Co-authorship network of co-authors of James W. Hainer

This figure shows the co-authorship network connecting the top 25 collaborators of James W. Hainer. A scholar is included among the top collaborators of James W. Hainer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Hainer. James W. Hainer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brott, David, Stephen T. Furlong, Scott Adler, et al.. (2015). Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. Drug Design Development and Therapy. 9. 3191–3191. 12 indexed citations

Porta, Massimo, James W. Hainer, Anna Malm, et al.. (2011). Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled diabetic retinopathy candesartan trials. Diabetologia. 54(6). 1298–1303. 31 indexed citations

Schaefer, Franz, Johan Van de Walle, Aleksandra Żurowska, et al.. (2010). Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. Journal of Hypertension. 28(5). 1083–1090. 47 indexed citations

Barrett, Jeffrey S., Ekaterina Gibiansky, R. Hull, et al.. (2009). Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. International Journal of Clinical Pharmacology and Therapeutics. 39(10). 431–46. 19 indexed citations

Trachtman, Howard, James W. Hainer, Jennifer Sugg, et al.. (2008). Efficacy, Safety, and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Children Aged 6 to 17 Years. Journal of Clinical Hypertension. 10(10). 743–750. 51 indexed citations

Desai, Akshay S., Karl Swedberg, John J.V. McMurray, et al.. (2007). Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. Journal of the American College of Cardiology. 50(20). 1959–1966. 129 indexed citations

Batisky, Donald L., Jonathan M. Sorof, Jennifer Sugg, et al.. (2007). Efficacy and Safety of Extended Release Metoprolol Succinate in Hypertensive Children 6 to 16 Years of Age: A Clinical Trial Experience. The Journal of Pediatrics. 150(2). 134–139.e1. 45 indexed citations

Hainer, James W. & Jennifer Sugg. (2007). Metoprolol succinate extended release/hydrochlorothiazide combination tablets.. PubMed. 3(3). 279–88. 10 indexed citations

McMurray, John J.V., James B. Young, Mark E. Dunlap, et al.. (2006). Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial. American Heart Journal. 151(5). 985–991. 67 indexed citations

10.

Izzo, Joseph L., et al.. (2004). Antihypertensive Efficacy of Candesartan‐Lisinopril in Combination vs. Up‐Titration of Lisinopril: The AMAZE Trials. Journal of Clinical Hypertension. 6(9). 485–493. 25 indexed citations

11.

Hainer, James W., et al.. (2004). Extending the Role of Antithrombotic Agents: An Example Based on the Low-Molecular-Weight Heparin, Tinzaparin. Seminars in Thrombosis and Hemostasis. 30. 3–9. 5 indexed citations

12.

Hainer, James W., Donald J. Sherrard, Suzanne K. Swan, et al.. (2002). Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. American Journal of Kidney Diseases. 40(3). 531–538. 28 indexed citations

13.

Barrett, Jeffrey S., Christopher Assaid, Michael J. Fossler, et al.. (2002). Dosing in Heavy-weight/Obese Patients with the LMWH, Tinzaparin: A Pharmacodynamic Study. Thrombosis and Haemostasis. 87(5). 817–823. 81 indexed citations

14.

Barrett, Jeffrey S., James W. Hainer, David M. Kornhauser, et al.. (2001). Anticoagulant Pharmacodynamics of Tinzaparin Following 175 IU/kg Subcutaneous Administration to Healthy Volunteers. Thrombosis Research. 101(4). 243–254. 19 indexed citations

15.

Fossler, Michael J., et al.. (2001). Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers. American Journal of Health-System Pharmacy. 58(17). 1614–1621. 10 indexed citations

16.

Hainer, James W., et al.. (1997). DMP 504, a novel hydrogel bile acid sequestrant: III. Safety, tolerability, and cholesterol-lowering in healthy hypercholesterolemic subjects. Drug Development Research. 41(2). 76–84. 5 indexed citations

17.

Shimshick, Edward J., et al.. (1997). DMP 504, a novel hydrogel bile acid sequestrant: I. equilibrium binding properties and computer simulation of human bile flow. Drug Development Research. 41(2). 58–64. 9 indexed citations

18.

Hainer, James W., James G. Terry, Peter J. Gillies, et al.. (1994). Effect of the acyl-CoA: cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clinical Pharmacology & Therapeutics. 56(1). 65–74. 55 indexed citations

19.

Livak, Kenneth J. & James W. Hainer. (1994). A microtiter plate assay for determining apolipoprotein E genotype and discovery of a rare allele. Human Mutation. 3(4). 379–385. 14 indexed citations

20.

Hainer, James W., et al.. (1974). Pulmonary Monosporosis: Report of a Case with Precipitating Antibody. CHEST Journal. 66(5). 601–603. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact